See more : That Marketing Solution, Inc. (TSTS) Income Statement Analysis – Financial Results
Complete financial analysis of Tarsus Pharmaceuticals, Inc. (TARS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tarsus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- VELTRA Corporation (7048.T) Income Statement Analysis – Financial Results
- Bushveld Minerals Limited (BMN.L) Income Statement Analysis – Financial Results
- Ermenegildo Zegna N.V. (ZGN) Income Statement Analysis – Financial Results
- Newmont Corporation (NEM) Income Statement Analysis – Financial Results
- UV Germi SA (ALUVI.PA) Income Statement Analysis – Financial Results
Tarsus Pharmaceuticals, Inc. (TARS)
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.45M | 25.82M | 57.03M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.59M | 955.00K | 2.08M | 246.00K | 74.00K | 1.00K |
| Gross Profit | 15.85M | 24.86M | 54.95M | -246.00K | -74.00K | -1.00K |
| Gross Profit Ratio | 90.87% | 96.30% | 96.36% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.31M | 42.62M | 41.71M | 18.83M | 3.16M | 901.00K |
| General & Administrative | 0.00 | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.70M | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Other Expenses | 0.00 | 86.00K | -73.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 159.01M | 87.57M | 67.11M | 27.00M | 4.30M | 1.35M |
| Cost & Expenses | 160.61M | 88.53M | 69.18M | 27.00M | 4.30M | 1.35M |
| Interest Income | 10.34M | 3.50M | 36.00K | 188.00K | 40.00K | 0.00 |
| Interest Expense | 3.35M | 2.20M | 0.00 | 188.00K | 40.00K | 0.00 |
| Depreciation & Amortization | 877.00K | 789.00K | 606.00K | 246.00K | 74.00K | 1.00K |
| EBITDA | -131.67M | -59.11M | -13.17M | -26.56M | -4.56M | -1.35M |
| EBITDA Ratio | -754.69% | -229.03% | -18.55% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.16M | -62.71M | -12.16M | -27.00M | -4.30M | -1.35M |
| Operating Income Ratio | -820.53% | -242.92% | -21.32% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.27M | 617.00K | -1.62M | 188.00K | -371.00K | 32.00K |
| Income Before Tax | -135.89M | -62.10M | -13.77M | -26.81M | -4.67M | -1.32M |
| Income Before Tax Ratio | -778.89% | -240.53% | -24.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 55.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income Ratio | -778.89% | -240.51% | -24.25% | 0.00% | 0.00% | 0.00% |
| EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EPS Diluted | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Weighted Avg Shares Out | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
| Weighted Avg Shares Out (Dil) | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
Tarsus to submit application for new eye treatment to FDA in 2022
Tarsus Pharmaceuticals Inc. said Monday that a Phase 2b/3 clinical trial evaluating an experimental treatment for a type of ocular disease met the study's primary and secondary endpoints. However, the stock was down 15.3% in trading on Monday afternoon.
Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has reported topline data from Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in patients with Demodex blepharitis. 81% of patients achieved a significant, clinically meaningful collarette cure compared to 23% of those on the vehicle...
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related discontinuations, demonstrating the potential of TP-03 to treat Demodex blepharitis, a disease with no FDA-approved...
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with...
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with...
Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention
Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with...
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021
Source: https://incomestatements.info
Category: Stock Reports